RxDoctor Payments Data

Lisa Lefkovits, MD

Internal Medicine · Marietta, GANPI 1962560128

Payments from drug & device makers

$14,418in general payments, 2019–2025

Across 335 payments — averaging $43.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$7K
  • UCB, Inc.$887
  • AbbVie$872
  • Lilly USA, LLC$730
  • Novo Nordisk$454
  • Novartis$411
  • plus $4K from 53 others

What the payments were for

  • Speaking & faculty fees$7,20850%
  • Travel & lodging$1011%
  • Food & beverage$7,10849%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,418 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$187,978
Medicare patients
377
Services billed
4,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$30,550
MounjaroTirzepatide23$23,735
OzempicSemaglutide12$20,434
LinzessLinaclotide16$12,483
SynthroidLevothyroxine Sodium45$5,139
Levothyroxine Sodium286$3,973
Estradiol18$2,939
Atorvastatin Calcium301$2,251
Rosuvastatin Calcium119$1,806
Escitalopram Oxalate95$1,544
Duloxetine Hcl71$1,250
Gabapentin66$1,240
Wixela InhubFluticasone Propion/Salmeterol12$1,211
Ezetimibe64$1,204
Bupropion Hcl SrBupropion Hcl41$1,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$312$30,55030 claims
Lilly USA, LLCMounjaro$730$23,73523 claims
Novo NordiskOzempic$454$20,43412 claims
AbbVieLinzess, Synthroid$872$17,62261 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$3,973286 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →